Elsevier

Drug Resistance Updates

Volume 4, Issue 6, December 2001, Pages 392-401
Drug Resistance Updates

Review
Anticancer therapy with novel tubulin-interacting drugs

https://doi.org/10.1054/drup.2002.0230Get rights and content

Abstract

Antimitotic agents that target tubulin, including the taxanes and vinca alkaloids, are important components of current anticancer therapy. Whilst these antimitotic drugs are highly effective in the treatment of a number of cancers, both acquired and intrinsic resistance to these agents is a major clinical problem. Furthermore, the systemic toxicity, and in some cases lack of oral availability, make these agents less than ideal. Recently much effort has been directed on the isolation and synthesis of new antimitotic drugs that target the tubulin/microtubule system and display efficacy against drug-refractory carcinomas. Newly described compounds include structurally diverse natural products, such as dolastatin, epothilones and discodermolide, derivatives and structural analogues of traditional antimitotics, and novel synthetic molecules. Additionally, new developments in drug targeting are improving efficacy and therapeutic indices of traditional agents. A number of promising ‘new generation’ antimitotics are now undergoing clinical testing. These new agents are reviewed here in terms of their mechanism(s) of action on microtubules, effectiveness against drug-resistant tumour cells and clinical potential.

References (112)

  • K.W. Wood et al.

    Past and future of the mitotic spindle as an oncology target

    Curr Opin Pharmacol

    (2001)
  • M.O. Bradley et al.

    Tumor targeting by conjugation of DHA to paclitaxel

    J Control Rel

    (2001)
  • S.J. Haggarty et al.

    Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis

    Chem Biol

    (2000)
  • A.W. Tolcher et al.

    A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors

    Ann Oncol

    (2000)
  • M.M. Gottesman et al.

    Biochemistry of multidrug resistance mediated by the multidrug transporter

    Annu Rev Biochem

    (1993)
  • M. Kavallaris

    The role of Multidrug Resistance-associated Protein (MRP) gene expression in drug resistance

    Anti-Cancer Drugs

    (1997)
  • P. Borst et al.

    A family of drug transporters: the multidrug resistance-associated proteins

    J Natl Cancer Inst

    (2000)
  • D.D. Ross et al.

    Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines

    J Natl Cancer Inst

    (1999)
  • M. Kavallaris et al.

    Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes

    J Clin Invest

    (1997)
  • C.A. Burkhart et al.

    The role of β-tubulin isotypes in resistance to antimitotic drugs

    Biochim Biophys Acta

    (2001)
  • M. Kavallaris et al.

    Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukaemia cells

    Cancer Res

    (2001)
  • L. He et al.

    Mutations in β-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines

    Mol Cancer Therapeut

    (2001)
  • P.B. Schiff et al.

    Taxol stabilizes microtubules in mouse fibroblast cells

    Proc Natl Acad Sci USA

    (1980)
  • M.A. Jordan et al.

    Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations

    Proc Natl Acad Sci USA

    (1993)
  • W.B. Derry et al.

    Substoichiometric binding of taxol suppresses microtubule dynamics

    Biochemistry

    (1995)
  • V.K. Ngan et al.

    Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules

    Cancer Res

    (2000)
  • J. Fahy

    Modifications in the “upper” velbenamine part of the vinca alkaloids have major implications for tubulin interacting activities

    Curr Pharm Des

    (2001)
  • E.K. Rowinsky et al.
  • B.T. Hill

    Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers

    Curr Pharm Des

    (2001)
  • V.K. Ngan et al.

    Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic vinca alkaloids vinorelbine and its newer derivative vinflunine

    Mol Pharmacol

    (2001)
  • T. Okouneva et al.

    How do the newer vinca alkaloids vinflunine and vinorelbine block mitosis

    Proc Am Assoc Cancer Res

    (2002)
  • S.E. Holwell et al.

    Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model

    Br J Cancer

    (2001)
  • A. Kruczynski et al.

    Significant antiangiogenic activity and marked inhibition of growth of an orthotopic colon cancer model and colon cancer liver metastases by vinflunine, the most recent vinca alkaloid in clinical development

    Proc Am Assoc Cancer Res

    (2002)
  • C. Etiévant et al.

    Markedly diminished drug-resistance inducing properties of vinflunine (20′,20′- difluoro-3′,4′- dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro, with clinical implications

    Cancer Chemother Pharmacol

    (2001)
  • D. Panda et al.

    Antiproliferative mechanisms of action of cryptophycin-52:Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends

    Proc Natl Acad Sci USA

    (1998)
  • K. Lu et al.

    Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells

    Cancer Chemother Pharmacol

    (2001)
  • B.A. Teicher et al.

    Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumour xenografts

    In Vivo

    (2000)
  • K. Menon et al.

    Antitumour activity of cryptophycins: effect of infusion time and combination studies

    Cancer Chemother Pharmacol

    (2000)
  • C. Shih et al.

    Cryptophycins: A novel class of potent antitumor depsipeptides

    Curr Pharm Des

    (2001)
  • R. Bai et al.

    Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions

    Mol Pharmacol

    (1995)
  • H.C. Pitot et al.

    Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors

    Clin Cancer Res

    (1999)
  • U. Vaishampayan et al.

    Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma

    Clin Cancer Res

    (2000)
  • K. Margolin et al.

    Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium

    Invest New Drugs

    (2002)
  • M. Otani et al.

    TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death

    Jpn J Cancer Res

    (2000)
  • T. Natsume et al.

    Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin

    Jpn J Cancer Res

    (2000)
  • G. Bacher et al.

    D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity

    Cancer Res

    (2001)
  • S.K. Tahir et al.

    A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors

    Cancer Res

    (2001)
  • B.G. Szczepankiewicz et al.

    New antimitotic agents with activity in multi-drug resistant cell lines and in vivo efficacy in murine tumor models

    J Med Chem

    (2001)
  • M.C. Wani et al.

    Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumour agent fromtaxus brevifolia

    J Am Chem Soc

    (1971)
  • S.B. Horwitz

    Mechanism of action of taxol

    Trends Pharmacol Sci

    (1992)
  • Cited by (129)

    • Novel combretastatin A-4 derivative containing aminophosphonates as dual inhibitors of tubulin and matrix metalloproteinases for lung cancer treatment

      2022, European Journal of Medicinal Chemistry
      Citation Excerpt :

      Up still now, some of FDA approved microtubule-targeting agents are natural products or their derivatives, such as paclitaxel, vincristine and docetaxel, which are widely used and highly effective in the treatment of many solid tumors. However, the clinical utilization of these microtubule-targeting agents is primarily impeded by several defects: (i) the development of drug resistance and adverse reactions, (ii) poor solubility and low membrane permeability, (iii) complex synthesis, respectively [10–13]. Thus, these have encouraged pharmaceutical chemists to discovery novel microtubule-targeting agents for cancer therapy (see Scheme 1).

    • Interactome Analysis of Microtubule-targeting Agents Reveals Cytotoxicity Bases in Normal Cells

      2017, Genomics, Proteomics and Bioinformatics
      Citation Excerpt :

      In addition, this network plays a regulatory role in cell migration and adhesion as well [6,7]. Microtubule-targeting agents (MTAs) can affect microtubule stability, leading to disruption of the mitotic spindle and cell death [8], and are therefore one of the most effective classes of drugs used in chemotherapy against cancer. According to their binding property with tubulin, MTAs are classified as stabilizing agents (known as vinca alkaloids) [9,10], which bind the tubulin polymer, and destabilizers (known as taxanes) [11–13], which bind tubulin dimers.

    View all citing articles on Scopus
    View full text